


Serial No.: 08/167,846  
Group Art Unit No.: 1201

Please add new claims 29-51, as follows:

~~29.~~ A method of treatment of a condition wherein a 5-HT<sub>1</sub>-like agonist is indicated, which comprises administering to a subject in need thereof an effective amount of a compound of general formula (I):



Formula (I)

wherein :

R<sup>1</sup> represents -(CH<sub>2</sub>)<sub>n</sub>CONR<sup>5</sup>R<sup>6</sup>;

R<sup>5</sup> and R<sup>6</sup> each independently represent hydrogen, methyl, ethyl or propyl;

n represents 0; and

R<sup>2</sup> and R<sup>3</sup> each independently represent hydrogen, methyl or ethyl;

or a physiologically acceptable salt thereof.


~~30.~~ The method according to claim ~~29~~ wherein the condition is migraine.

~~31.~~ The method according to claim ~~29~~ wherein the condition is cluster headache.

~~32.~~ The method according to claim ~~29~~ wherein the condition is headache associated with vascular disorders.

~~51.~~ A compound of general formula (I):

Serial No.: 08/167,846  
Group Art Unit No.: 1201



Formula (I)

wherein:

R¹ represents  $-(CH_2)_nCONR^5R^6$ ;

R⁵ and R⁶ each independently represent hydrogen, methyl, ethyl or propyl;

n represents 0; and

R² and R³ each independently represent hydrogen, methyl or ethyl;

or a physiologically acceptable salt thereof.

6  
34.

The compound of claim 33 wherein R⁵ and R⁶ are hydrogen or methyl.

7  
35.

The compound as claimed in claim 33, wherein:

R¹ represents  $-(CH_2)_nCONR^5R^6$ ;

R⁵ and R⁶ are each hydrogen;

n represents 0; and

R² is hydrogen and R³ is methyl;

or a physiologically acceptable salt thereof.

8  
36.

A pharmaceutical composition comprising a compound of formula (I) according to claim 33, or a physiologically acceptable salt thereof and a physiologically acceptable carrier.

9  
37.

A method of treatment of a condition wherein a 5-HT<sub>1</sub>-like agonist is indicated, which comprises administering to a subject in need thereof an effective amount of a compound of claim 33.

10  
38.

The method according to claim 37 wherein the condition is migraine.

11  
39.

The method according to claim 37 wherein the condition is cluster headache.

Serial No.: 08/167,846  
Group Art Unit No.: 1201

~~112~~  
~~40.~~ The method according to claim ~~37~~ wherein the condition is headache associated with vascular disorders.

~~113~~  
~~41.~~ A pharmaceutical composition comprising a compound of formula (I) according to claim ~~35~~, or a physiologically acceptable salt thereof and a physiologically acceptable carrier.

~~114~~  
~~42.~~ A compound of formula (I) which is ~~(+)~~-3-amino-6-carboxamido-1,2,3,4-tetrahydrocarbazole, or a salt, solvate or hydrate thereof.

~~115~~  
~~43.~~ A compound of formula (I) which is ~~(-)~~-3-amino-6-carboxamido-1,2,3,4-tetrahydrocarbazole, or a salt, solvate or hydrate thereof.

~~116~~  
~~44.~~ A compound of formula (I) which is 3-methylamino-6-carboxamido-1,2,3,4-tetrahydrocarbazole, or a salt, solvate or hydrate thereof.

~~117~~  
~~45.~~ A compound of formula (I) which is 3-ethylamino-6-carboxamido-1,2,3,4-tetrahydrocarbazole, or a salt, solvate or hydrate thereof.

~~118~~  
~~46.~~ A compound of formula (I) which is 3-dimethylamino-6-carboxamido-1,2,3,4-tetrahydrocarbazole, or a salt, solvate or hydrate thereof.

~~119~~  
~~47.~~ A method of treatment of a condition wherein a 5-HT<sub>1</sub>-like agonist is indicated, which comprises administering to a subject in need thereof an effective amount of a compound of claim ~~44~~.

~~120~~  
~~48.~~ The method according to claim ~~44~~ wherein the condition is migraine.

~~121~~  
~~49.~~ The method according to claim ~~44~~ wherein the condition is cluster headache.

~~122~~  
~~50.~~ The method according to claim ~~44~~ wherein the condition is headache associated with vascular disorders.

40